Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report

Clin Lung Cancer. 2021 Sep;22(5):e703-e707. doi: 10.1016/j.cllc.2021.01.009. Epub 2021 Jan 27.

Authors

Thomas Waddington¹, Isa Mambetsariev², Rebecca Pharaon², Jeremy Fricke², Angel Ray Baroz², Hannah Romo², Bassam Ghanem², Stacy Gray², Ravi Salgia³

Affiliations

¹ Department of Medicine, Division of Pulmonary and Critical Care Medicine, City of Hope National Medical Center, Duarte, CA.
² Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA.
³ Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA. Electronic address: rsalgia@coh.org.

No abstract available

Keywords: Germline mutation; Immunotherapy; NSCLC; Olaparib; Precision medicine.

Publication types

Case Reports
Research Support, N.I.H., Extramural

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / administration & dosage*
BRCA2 Protein / genetics*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Drug Therapy, Combination
Female
Germ-Line Mutation*
Humans
Lung Neoplasms / drug therapy*
Maternal Inheritance*
Phthalazines / administration & dosage*
Piperazines / administration & dosage*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
BRCA2 Protein
BRCA2 protein, human
Phthalazines
Piperazines
pembrolizumab
olaparib

Grants and funding